Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer

Journal of Thoracic Oncology

Volumn 2, Issue 12, 2007, Pages 1112-1116

  Davies, Angela M ^a,d   Ho, Cheryl ^b   Metzger, Alex S ^c   Beckett, Laurel A ^a   Christensen, Scott ^a   Tanaka, Michael ^a   Lara, Primo N ^a   Lau, Derick H ^a   Gandara, David R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

^c Marin Cancer Institute   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bortezomib; Non small cell lung cancer; Pemetrexed; Phase I; Proteasome

Indexed keywords

BORTEZOMIB; CYANOCOBALAMIN; DEXAMETHASONE; FOLIC ACID; PEMETREXED;

ADENOID CYSTIC CARCINOMA; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BLEEDING; BREAST CARCINOMA; CANCER GROWTH; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEHYDRATION; DIARRHEA; DISEASE COURSE; DIZZINESS; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG FATALITY; DRUG FEVER; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; FEMALE; FLUID THERAPY; GASTROINTESTINAL CARCINOMA; HEAD AND NECK CARCINOMA; HUMAN; INFECTION; KIDNEY DYSFUNCTION; LUNG CARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CARCINOMA; RECOMMENDED DRUG DOSE; SARCOMA; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; THYMUS CANCER; TREATMENT OUTCOME;

EID: 37349100108     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31815ba7d0     Document Type: Article

References (14)

1. Adams J.. Development of the proteasome inhibitor PS-341. Oncologist 2002;7:9-16.
2. Edelman MJ. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer. Clin Lung Cancer 2005;2 (7 Suppl):S64-S66.
3. Teicher BA, Ara G, Herbst R, et al. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999;5:2638-2645.
4. Yunmbam MK, Li QQ, Mimnaugh EG, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol 2001;19:741-748.
5. Orlowski RZ, Nagler A, Sonneveld P, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-3901.
6. Gumerlock PH, Pryde BJ, Kimura T IV, et al, for the University of California, Davis, Cancer Center, Sacramento, CA. Enhanced cytotoxicity of docetaxel OSI-774 combination in non-small cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 22:2003 (abstract 2661).
7. Visbal AL, Williams BA, Nichols FC III, et al. Gender differences in non-small-cell lung cancer survival: an analysis of 4,618 patients diagnosed between 1997 and 2002. Ann Thorac Surg 2004;78:209-215.
8. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma [see comment]. J Clin Oncol 2003;21:2636-2644.
9. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-1597.
10. Davies AM, Lara PN, Lau DH, et al. The proteasome inhibitor, bortezomib, in combination with gemcitabine (Gem) and carboplatin (Carbo) in advanced non-small cell lung cancer (NSCLC): final results of a phase I California Cancer Consortium study (Abstract). J Clin Oncol 2004;22:7106.
11. Davies AM, Ho C, Lara PN, et al Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer 2006;7:385-388.
12. Voortman J, Resende TP, Abou El Hassan MA, et al. TRAIL therapy in non-small cell lung cancer cells: sensitization to death receptor-mediated apoptosis by proteasome inhibitor bortezomib. Mol Cancer Ther 2007;6:2103-2112.
13. Liu X, Yue P, Chen S, et al. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 2007;67:4981-4988.
14. Zangari M, Esseltine D, Cavallo F, et al. Predictive value of alkaline phosphatase for response and time to progression in bortezomib-treated multiple myeloma patients. Am J Hematol 2007;82:831-833.